Teneligliptin: a review on cardio-renal safety

Patel, Dixit; Sharma, Ramandeep; Patel, Himanshu; Barkate, Hanmant

doi:10.18203/2319-2003.ijbcp20160738

Cited by 8 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 25 ] When teneligliptin was used in various clinical studies as monotherapy or combination therapy with duration ranging from 4 weeks to 1 year, none of these trials have reported any drug-related CV adverse effects. [ 26 ] However, one randomized, double-blind study observed a significant QT/QTc prolongation with 160 mg dose of teneligliptin in 240 healthy adult subjects. [ 27 ] It is advisable to exercise the caution in patients with diabetic patients with concurrent diseases such as arrhythmia and ischemia, and patients co-administered with drugs known for QT prolongation such as class IA or class III antiarrhythmic drugs.…”

Section: Urrent S Tatus On C mentioning

confidence: 99%

A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors

Khalse

Bhargava

2018

Indian J Endocr Metab

View full text Add to dashboard Cite

The U.S. Food and Drug Administration issued a guidance for pharmaceutical industry defining preapproval and postapproval requirements for the demonstration of cardiovascular (CV) safety for all new medications developed for glycemic management in type 2 diabetes. However, results published from the studies of dipeptidyl peptidase-4 (DPP-4) inhibitors are conflicting with regard to different CV endpoints. Upcoming CV outcome studies perhaps will be able to provide additional insights related to diabetes management and help to provide the answers to some of these concerns. This article provides a brief overview regarding how various CV safety evidence of DPP-4 inhibitor evolved over time that highlights possible implication in clinical practice and translates them into effective diabetes management.

show abstract

Section: Urrent S Tatus On C mentioning

confidence: 99%

A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors

Khalse

Bhargava

2018

Indian J Endocr Metab

View full text Add to dashboard Cite

show abstract

“…It is indeed a global health challenge for the 21st century [1]. If the present trend of DM continues, by 2045, almost 134 million people will have diabetes in the world and by 2030, DM may afflict up to 79.4 million individuals in India while China (42.3 million) and the United States (30.3 million) will also see significant increases in those affected by the disease [2][3]. Based on the statistics of the International Diabetes Federation (IDF) 2015 report, around 69.2 million diabetic patients live in India, the second-most highly prevalent country after China (109.6 million) [4].…”

Section: Introductionmentioning

confidence: 99%

“…According to the health projection report of IDF, as estimated in 2015, if the current trend of DM continues, by 2040, India will have about 123.5 million DM patients [4]. Among the uncountable factors behind this unexpected increase of DM prevalence in India, the one that must be stated here the rapid shift in the Indian economy [3,5].…”

Section: Introductionmentioning

confidence: 99%

“…Indeed, prior studies have demonstrated that combination therapy with an SGLT2 inhibitor and a DPP-4 inhibitor was effective and well-tolerated [12][13][14]. Among various DPP-4 inhibitors, teneligliptin has been approved for the management of type 2 DM in some countries, namely, Japan (2012), South Korea (2014), and India (2015) [3]. In Japan, the drug teneligliptin has been licensed for administration at standard (20 mg/day) and high (40 mg/day) doses for glycemic control [15].…”

Section: Introductionmentioning

confidence: 99%

“…In Japan, the drug teneligliptin has been licensed for administration at standard (20 mg/day) and high (40 mg/day) doses for glycemic control [15]. Teneligliptin has shown good tolerance and is capable of glycemic control as monotherapy or add-on therapy in patients with type 2 DM [3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the Safety and Efficacy of Teneligliptin at a Higher Dose in Indian Type 2 Diabetes Patients: A Retrospective Analysis

Mitra

Ray²

2020

Cureus

View full text Add to dashboard Cite

Background and aim While diabetes mellitus (DM) is occupying the topmost global epidemic position, India is harboring a challenging number of type 2 DM patients in the world. This devastating picture of the health sector in India requires the availability of more cost-effective, context-specific, and safer drugs for DM management. This study aimed to evaluate the safety and efficacy of teneligliptin in Indian patients with type 2 DM inadequately controlled with diet, exercise, and a maximal dose of metformin treatment. Materials and methods This was a retrospective, observational, and single-center study conducted at a diabetic clinic in India in type 2 DM patients who have been treated with teneligliptin 40 mg once daily as add-on therapy with diet, exercise, and the maximal tolerable dose of metformin for three months. The study was observational, where the data collection was through self-reporting and an observational study conducted over one year (September 2018 to August 2019). A total of 100 patients were enrolled in the study (male 69% and female 31%). Patients with available data for fasting plasma glucose (FPG), postprandial plasma glucose (2h PPG), glycated hemoglobin (HbA1c), renal function parameters, such as urinary albumin to creatinine ratio (UACR), and electrocardiogram (ECG) at baseline and three months after treatment were enrolled in the study. Results There was a significant reduction in fasting blood sugar (P=<0.001), postprandial blood sugar (P=<0.001), and HbA1c (P=<0.001) at the end of the three months treatment in comparison to the baseline level and in the primary outcomes of this study as compared to baseline. The teneligliptin treatment did not cause any significant reduction in body mass index (BMI) before and after treatment. When we compared the secondary outcomes, the indicator of renal function as expressed through the albumin-to-creatinine ratio (ACR; P=0.052), there was a borderline change in ACR from baseline to three months. The mean corrected QT interval at screening baseline was 429.7 ± 8.89 milliseconds while after three months, it was 429.1 ± 8.68 milliseconds, which was statistically insignificant. Conclusion The current results demonstrated a high level of efficacy as an add-on therapy of teneligliptin 1 2

show abstract

One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus

Seetharaman

Pawar

Advani

2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

Diabetes mellitus was considered a fatal malady until the discovery, extraction and commercial availability of insulins. Numerous other classes of drugs ranging from sulfonylureas to sodium‐glucose co‐transporter‐2 inhibitors were then marketed. However, with the prevalence of diabetes mellitus increasing every year, many more drugs and therapies are under investigation. This review article aimed to summarize the significant developments in the pharmacotherapy of diabetes mellitus and outline the progress made by the recent advances, 100 years since insulins were first extracted successfully. Insulin analogues and insulin delivery pumps have further improved glycaemic control in diabetes mellitus. Cardiovascular and renal outcome trials have changed the landscape of diabetology, with some of these drugs also efficacious in nondiabetics. Newer drug delivery systems are being evaluated to improve the efficacy and reduce the dosing frequency and adverse effects of antidiabetics. Some newer drugs with novel mechanisms of action targeting type 1 and type 2 diabetes have also shown promise in recent clinical trials. These drugs include dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide 1‐agonists, glucokinase activators, anti‐CD3 monoclonal antibodies and glimins. Their efficacy needs to be evaluated in larger studies.

show abstract

Teneligliptin: a review on cardio-renal safety

Cited by 8 publications

References 16 publications

A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors

A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors

Evaluation of the Safety and Efficacy of Teneligliptin at a Higher Dose in Indian Type 2 Diabetes Patients: A Retrospective Analysis

One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus

Contact Info

Product

Resources

About